{"denoms":[{"counts":[{"groupId":"BG000","value":"33"}],"units":"Participants"}],"groups":[{"description":"Patients with non-operable and progressing metastatic cutaneous melanoma, received up to 24 doses of GSK2241658A Cancer Immunotherapeutic, provided that at each tumor evaluation time point, the clinical criteria to continue the treatment were met, including patients having a clinical response.","id":"BG000","title":"NY-ESO 1 Group"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"14.4","value":"65.7"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"16"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"17"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"33"}]}],"title":"White - Caucasian / European Heritage"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}]}